COLL Q3 2021 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$79M-0.4% YoY

Gross Profit

$46M58.5% margin

Operating Income

$14M17.9% margin

Net Income

$8M10.2% margin

EPS (Diluted)

$0.22

QoQ Revenue Growth

-4.9%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$742M

Total Liabilities

$491M

Stockholders' Equity

$251M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$79M	-0.4%
Gross Profit	$46M	$48M	-4.3%
Operating Income	$14M	$20M	-27.9%
Net Income	$8M	$11M	-28.7%

Revenue Segments

Nucynta

$49M38%

Xtampza

$30M24%

Nucynta Ir

$29M23%

Nucynta Er

$20M15%